Roche DJO et al., 2016-06: A pilot human trial of ivermectin for alcohol use disorder: a randomized placebo-controlled crossover in 11 drinkers found 30 mg daily was safe alongside alcohol but did not reduce craving or the subjective response to alcohol.
IVM did not reduce cue-induced craving nor did it significantly affect subjective response to alcohol.
Roche DJO et al., 2016-06: A pilot human trial of ivermectin for alcohol use disorder: a randomized placebo-controlled crossover in 11 drinkers found 30 mg daily was safe alongside alcohol but did not reduce craving or the subjective response to alcohol. Randomized, placebo-controlled, crossover pilot study, N=11 individuals with alcohol use disorder, United States (Los Angeles); ivermectin 30 mg oral once daily combined with an intoxicating intravenous alcohol dose (0.08 g/dl), inpatient observation. Comparator: placebo. Safety endpoint met (no increase in adverse effects); efficacy endpoints negative. Declared conflicts include consultancy for GSK and medications supplied by Pfizer and Medicinova to one author. Bearing PARTLY SUPPORTS: the human evidence establishes safety and dosing, not efficacy, and the paper says so. Study type: randomized trial.
